CHEK1 and cancer: Mischel et al. demonstrated that an experimental inhibitor (BBI‐2779, related to CHK1 inhibition) could exploit the DNA copying difficulties in eccDNA‐positive cancer cells, causing catastrophic replication failure when combined with targeted therapy [40].